We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Shares of Ionis Pharma (IONS) are Falling Today
Read MoreHide Full Article
On Monday, shares of Ionis Pharmaceuticals Inc. (IONS - Free Report) are falling, down about 10% in morning trading after the company announced results from its 15-month long Phase 3 NEURO-TTR Study of its drug Inotersen (IONIS-TTRrx).
Inotersen is being tested for the treatment of the inherited disorder familial amyloid polyneuropathy (FAP). While the study met both primary efficacy endpoints that demonstrated statistically valid treatment benefits in comparison to the placebo, there were some concerning side effects.
Three study participants developed thrombocytopenia, or low blood platelets; two recovered, but one died from intracranial hemorrhage, and another patient stopped taking Inotersen due to non-serious thrombocytopenia. There were also four patients that stopped the treatment due to kidney problems, one from a renal observation, two from meeting a predefined renal stopping rule, and one from chronic renal insufficiency.
Ionis said that all five of these instances happened before enhanced monitoring was completely implemented, and that a review of the safety data is ongoing.
“We are grateful to the patients who participated in the NEURO-TTR study, along with their families, the investigators and the broader TTR amyloidosis community, for their dedication, commitment and support. We share the collective sense of urgency to bring a new treatment to patients and their families facing this devastating disease," said Brett P. Monia, senior vice president of drug discovery and franchise leader for oncology and rare diseases at Ionis Pharmaceuticals.
Currently, IONS is a #3 (Hold) on the Zacks Rank, with a VGM score of ‘B.’
5 Trades That Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today, Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why Shares of Ionis Pharma (IONS) are Falling Today
On Monday, shares of Ionis Pharmaceuticals Inc. (IONS - Free Report) are falling, down about 10% in morning trading after the company announced results from its 15-month long Phase 3 NEURO-TTR Study of its drug Inotersen (IONIS-TTRrx).
Inotersen is being tested for the treatment of the inherited disorder familial amyloid polyneuropathy (FAP). While the study met both primary efficacy endpoints that demonstrated statistically valid treatment benefits in comparison to the placebo, there were some concerning side effects.
Three study participants developed thrombocytopenia, or low blood platelets; two recovered, but one died from intracranial hemorrhage, and another patient stopped taking Inotersen due to non-serious thrombocytopenia. There were also four patients that stopped the treatment due to kidney problems, one from a renal observation, two from meeting a predefined renal stopping rule, and one from chronic renal insufficiency.
Ionis said that all five of these instances happened before enhanced monitoring was completely implemented, and that a review of the safety data is ongoing.
“We are grateful to the patients who participated in the NEURO-TTR study, along with their families, the investigators and the broader TTR amyloidosis community, for their dedication, commitment and support. We share the collective sense of urgency to bring a new treatment to patients and their families facing this devastating disease," said Brett P. Monia, senior vice president of drug discovery and franchise leader for oncology and rare diseases at Ionis Pharmaceuticals.
Currently, IONS is a #3 (Hold) on the Zacks Rank, with a VGM score of ‘B.’
5 Trades That Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today, Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>